Tekmira Presents Data on Hepatitis B Candidate TKM-HBV - Analyst Blog

An image of multiple stacks of coins
Credit: Shutterstock photo

Tekmira Pharmaceuticals Corp. ( TKMR ) presented encouraging preclinical data on its hepatitis B infection candidate, TKM-HBV, at the annual meeting of the Oligonucleotide Therapeutics Society. The company said that TKM-HBV demonstrated potent and rapid reduction in hepatitis B surface antigen in several preclinical models.

Tekmira is developing the candidate for the treatment of chronic hepatitis B infection and expects to file an Investigational New Drug application by the end of this year. The company plans to initiate a phase I study on TKM-HBV in early 2015.

As per company sources, approximately 350 million people are infected with hepatitis B virus (HBV) worldwide. In the U.S. alone there are approximately 1.4 million HBV chronically infected people. Several patients are not adequately treated using currently available treatments. Tekmira aims to address this unmet need with TKM-HBV.

Tekmira was in the news earlier this year when the FDA confirmed that it has modified the full clinical hold on the company's Ebola candidate, TKM-Ebola, to a partial clinical hold. The move allows the potential use of TKM-Ebola in patients who have a confirmed Ebola infection and individuals with suspected of being infected with the disease. The WHO has declared the Ebola epidemic a public health emergency of international concern. The current outbreak of the disease in Africa has claimed several lives.

We remind investors that in Jul 2014, the FDA had placed Tekmira's phase I study on the Ebola candidate on clinical hold due to safety concerns.

Tekmira carries a Zacks Rank #3 (Hold). Some better-ranked biotech stocks include Ligand Pharmaceuticals Inc. ( LGND ), Medivation Inc. ( MDVN ) and Auxilium Pharmaceuticals, Inc. ( AUXL ). While Ligand and Medivation are Zacks Rank #1 (Strong Buy) stocks, Auxilium holds a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


AUXILIUM PHARMA (AUXL): Free Stock Analysis Report

MEDIVATION INC (MDVN): Free Stock Analysis Report

LIGAND PHARMA-B (LGND): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More